Form 4: CytomX Therapeutics Director James R. Meyers Acquires Stock Options
SEC Form 4 Filing
Director James R. Meyers of CytomX Therapeutics acquired 38,000 stock options on May 15, 2024, exercisable at $1.96 per share.
Summary
- James R. Meyers, a director of CytomX Therapeutics, acquired 38,000 stock options on May 15, 2024.
- The exercise price of these options is $1.96 per share.
- The options vest on the earlier of May 15, 2025, or the date of the 2025 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director.
- The options expire on May 14, 2034.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing an insider transaction. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company directors.
Stakeholder Impact
- The acquisition of stock options by a director could be viewed positively by shareholders as it aligns the director's interests with the company's performance.
Key Dates
| Date | Description |
|---|---|
| 05/15/2024 | Date of the stock option acquisition. |
| 05/15/2025 | Earliest vesting date of the stock options (first anniversary of grant date). |
| 2025 Annual Meeting | Alternative vesting date of the stock options (date of the 2025 Annual Meeting of the Issuer's stockholders). |
| 05/14/2034 | Expiration date of the stock options. |
| 05/17/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.